Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

Abstract

PURPOSE To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense oligonucleotide to DNA methyltransferase 1 (DNMT1), which has been shown to reduce CpG island methylation and allow reexpression of tumor suppressor genes in vitro. EXPERIMENTAL DESIGN In this phase I, open-label study, patients with advanced solid malignancies were treated with escalating doses of MG98 administered as a continuous i.v. infusion over 7 days repeated every 14 days. Cohorts of three patients, which could be expanded to six patients, were studied. The maximum tolerated dose was defined as the highest dose at which no more than 33% of subjects experienced dose-limiting toxicity. Pharmacokinetic and pharmacodynamic parameters of MG98 were also characterized. RESULTS Thirty-three patients were treated at doses of 100 to 250 mg/m(2)/d MG98. MG98 was well tolerated with mild fatigue and myalgia, dose-limiting toxicity was asymptomatic transaminitis, and the maximum tolerated dose was 200 mg/m(2)/d. One patient achieved a partial response and another prolonged disease stabilization. Plasma half-life of MG98 was short (2 hours), drug concentrations reaching a dose-dependent steady state during infusion with a volume of distribution equivalent to plasma volume. Suppression of DNMT1 expression was observed in 26 of 32 patients studied. CONCLUSIONS MG98 was well tolerated with early evidence of clinical activity. Proof of mechanism was observed and measurement of DNMT1 expression in peripheral blood mononuclear cells may be useful in future phase II development.

DOI: 10.1158/1078-0432.CCR-08-2859

6 Figures and Tables

Statistics

050200920102011201220132014201520162017
Citations per Year

148 Citations

Semantic Scholar estimates that this publication has 148 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Plummer2009PhaseIS, title={Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.}, author={Ruth E. Plummer and Laura Maria Vidal and Melanie J. Griffin and Mark Lesley and J de Bono and Sally A. Coulthard and Julieann Sludden and L . Y . L . Siu and Eric Xueyu Chen and Amit M. Oza and Gregory K. Reid and A. Robert McLeod and Jeffrey M. Besterman and Chooi Peng Lee and Ian Judson and Hilary Allan Calvert and Alan V. Boddy}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2009}, volume={15 9}, pages={3177-83} }